SUMMARY Transglutaminase (TG) activity is increased in the mucosa of patients with coeliac disease. Among 18 patients with untreated coeliac disease we have found a significant decrease (p<O-OOl) in serum levels of TG activity (0.72 (0.23) mU/ml). There was no significant differences between 16 treated coeliacs (1P24 (0.28) mU/ml) and 30 normal controls (1.63 (0.42) mU/ml). To evaluate the connection between serum and mucosal TG activity we used the experimental model of methotrexate induced acute hypoplastic enteropathy in the rat. Transglutaminase activity was unchanged in serum and mucosa 24 and 48 hours after MTX administration, but increased in mucosa (2.606 (0.95) v basal 0.207 (0.026) mU/mg protein, p<0O001) and significantly decreased in serum at 72 hours (2.08 (0.38) v basal 5.56 (1P50) mU/ml, p<0.001) during intestinal cell proliferation. Activity of the enzyme in the mucosa and serum returned to baseline levels within 120 hours. This experimental animal model helps to explain the data of TG activity in human intestinal mucosa and serum reported in this study. Results are mean (SD).
Transglutaminase (TG) activity is present in a number of tissues'-3 including large and small intestine.45 In serum, TG activity is the result of the presence of coagulation factor XIIIa.6 Bruce and colleagues recently showed in in vitro experiments that gliadin is an excellent substrate for TG and found an increased enzyme activity in mucosal biopsies from patients with untreated and treated coeliac disease. On the basis of these findings they postulated a new pathogenetic hypothesis for coeliac disease: intestinal TG activity may be important in gliadin binding to tissues and thus in the pathogenesis of coeliac disease. ' Stimulated by their report, we have studied TG activity in serum and mucosa of coeliac patients in both remission and acute phases. To further evaluate the relationship between changes in TG activity in serum v intestinal tissues during atrophic damage of small bowel mucosa, we also studied TG activity modifications at those sites during acute enteropathy induced in rats by administration of methotrexate (MTX) which produces mucosal damage' resembling that of mucosal atrophy in coeliacs.
Methods

PATIENTS
Three groups of subjects were enrolled in the study: 18 patients with coeliac disease in relapse, 16 coeliacs in complete remission after at least one year of strict gluten free diet, and 30 healthy volunteers as control subjects. Most The incubation time and the optimal pH were chosen after preliminary study indicating the enzyme's activity as a linear function of the time up to 50 minutes and its progressive increase from pH 6 5 to pH 9.0.
A 30 il serum sample or tissue homogenate was added to 45 p.l of reaction mixture containing a final concentration of 0-25 mmol/l 14C-putrescine (Amersham, England), 50 mmol/l dithiothreitol, 10 mmol/l CaC12 and 4% (W/V) dimethylcasein in Tris HCI buffer (50 mmolIl) pH 9-0 with 0-1% Triton X 100. The reaction mixture was incubated and shaken at 37°C for 20 minutes. 20 Ill were spotted onto Whatman 3MM filter paper rounds (0 2 cm) and immediately plunged into 10% ice cold trichloroacetic acid (TCA) for 15 (0.38) mU/ml, p<0-001), it had returned to basal value at 96 h ( Fig. 1) . Figure 2 shows the comparison between mucosal sucrase and TG activity over the same period. The lowest level of sucrase activity was observed at 72 h, simultaneously with the peak increment of mucosal TG activity; the decrease was significant compared to baseline (40 (10) v 201 (18) U/g protein, p<0-001).
Discussion
Our data show for the first time the relationship between serum transglutaminase concentrations and coeliac disease activity. Mean serum TG values in coeliac patients on a normal diet, presenting a malabsorption syndrome and a total or subtotal mucosal atrophy at histological examination, were significantly lower than those of normal controls and coeliac patients in remission. Serum TG activity changes observed in untreated coeliac patients appeared unrelated to any defect of blood coagulation.
Our results on human jejunal mucosa confirm those reported in literature7 of an increased TG activity in coeliacs in relapse.
The acute MTX-induced enteropathy creates an experimental model somewhat resembling coeliac mucosal lesions: superficial atrophy and crypt hyperplasia. 13 14 Similarly, in the coeliac patients in relapse, an inverse relation between serum and intestinal TG changes during the phase of mucosal atrophy and repairing crypt proliferation, was observed in our rats. Whether the phenomenon is caused by exfoliation or loss of TG into the gut lumen or to reduced release of intestinal TG into serum, which would be needed locally for crypt hyperproliferation, remains a speculative hypothesis.
In conclusion our results show the existence of a decreased serum concentration of TG related to coeliac disease activity, suggesting that determination of this enzyme in serum of coeliac patients could be useful in monitoring disease remission. Furthermore we have shown an inverse relationship between serum and intestinal TG activity in MTX treated rats. 
